https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/research

The Latest

slacklining

This Week in HIV Research: So Many Relative Risks

July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.

By Barbara Jungwirth and Myles Helfand
white man black man

This Week in HIV Research: Existing Solutions Won't Close the Race Gap

June 18, 2020: Existing evidence-based interventions aren't enough to close HIV's racial gap; transgender patient outcomes in the HIV care continuum; meeting long-term needs of formerly incarcerated people; acute respiratory illness severity and HIV status.

By Barbara Jungwirth and Myles Helfand
Suraj Madoori, M.P.H., M.S.J., M.A. and Annette Gaudino

Will We Ever Have a Hepatitis C Vaccine? Two Activists Weigh in on the Challenges and Opportunities Ahead

A new injection of funding from Congress could be the catalyst for a future hepatitis C (HCV) vaccine.

By Terri Wilder, M.S.W.
snowball

This Week in HIV Research: HIV/COVID-19 Case Studies Gain Momentum

June 4, 2020: The latest on COVID-19 hospitalization among people with HIV; real-world success of hepatitis C treatment in coinfected patients with good health care; poverty and adherence in Canada's health system; demographic and socioeconomic factors associated with viral rebound.

By Barbara Jungwirth and Myles Helfand
doctor pointing at rectal model

Are Providers Ignoring Anal Sex as a Health Care Issue for Women at Risk for HIV and Cancer?

Recent studies examine the role anal sex is playing in HIV rates and anal cancer among women.

By Kenyon Farrow
discover opportunities

This Week in HIV Research: The Challenges of Our Assumptions

May 28, 2020: Anal lesion recurrence among women with HIV; non-alcoholic fatty liver disease frequency in lean patients; long-term efficacy for a smoking cessation intervention; non-lymphoid cancers following lymphoid malignancy.

By Barbara Jungwirth and Myles Helfand
selective focus image of Gilead Truvada for PrEP

This Week in HIV Research: PrEP So White

May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.

By Barbara Jungwirth and Myles Helfand
droplet of blood

This Week in HIV Research: How Dangerous Is Low-Level Viremia?

May 14, 2020: Recurring low-level viremia and morbidity/mortality risk; factors affecting severe bacterial infection in people with HIV; infective endocarditis cases on the rise; high rates of opioid use among U.S. veterans with HIV.

By Barbara Jungwirth and Myles Helfand
data

This Week in HIV Research: There’s No Such Thing as Too Much Data

May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.

By Barbara Jungwirth and Myles Helfand
fast pace of life

This Week in HIV Research: Special Considerations

April 30, 2020: Substance use relapse following opioid therapy for chronic pain; affect of cannabis on blood-brain barrier disruptions; PrEP considerations for adolescents; updated CDC contraceptive recommendations for women at risk for HIV.

By Barbara Jungwirth and Myles Helfand